title: Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres.
abstract: Single dose immunisation is a major goal in vaccine design. The purpose of this study was the development of a single dose delivery system for the SPf66 malaria vaccine, based on this antigen's microencapsulation in PLGA microspheres by double emulsion method. Results indicate that a single immunisation in mice and monkeys with the SPf66 malaria vaccine, encapsulated in a mixture of two formulations of PLGA microspheres, induced a remarkably high and long-lasting immune response as assessed by ELISA and Western Blott. This immune response was associated with a good protective capacity in Aotus monkeys, after experimental challenge, indicating that antigen integrity lasted following the microencapsulation process. PLGA biodegradable microspheres thus serve as an effective delivery system for the design of a single dose immunisation vaccine, such as the SPf66 synthetic malaria vaccine.
authors.affiliation: Fundación Instituto de Inmunologia de Colombia (FIDIC), Carrera 50, No. 2600, Santafé de Bogotá, Colombia.
authors.forename: J E
authors.initials: JE
authors.lastname: Rosas
authors.forename: J L
authors.initials: JL
authors.lastname: Pedraz
authors.forename: R M
authors.initials: RM
authors.lastname: Hernández
authors.forename: A R
authors.initials: AR
authors.lastname: Gascón
authors.forename: M
authors.initials: M
authors.lastname: Igartua
authors.forename: F
authors.initials: F
authors.lastname: Guzmán
authors.forename: R
authors.initials: R
authors.lastname: Rodríguez
authors.forename: J
authors.initials: J
authors.lastname: Cortés
authors.forename: M E
authors.initials: ME
authors.lastname: Patarroyo
mesh_terms: D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000008:administration & dosage; D001029:Aotus trivirgatus; D001672:Biocompatible Materials; D016503:Drug Delivery Systems; D019344:Lactic Acid; D017780:Malaria Vaccines / Q000008:administration & dosage*; D016778:Malaria, Falciparum / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D010963:Plasmodium falciparum / Q000276:immunology*; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D015800:Protozoan Proteins / Q000008:administration & dosage* / Q000276:immunology*; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000008:administration & dosage
chemical_list: D000534:Alum Compounds; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D001672:Biocompatible Materials; D017780:Malaria Vaccines; D011108:Polymers; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C041524:aluminum sulfate